[D-p-Cl-Phe6,Leu17]-VIP TFA

• CAT Number: I045805
• Molecular Formula: C150H240F3ClN44O44
• Molecular Weight: 3456.22
• Purity: ≥95%
• IUPAC Name: (3S)-3-[[(2R)-2-[2-[(2S)-1-[[(3R)-1-[[(2R)-1-[[(2S)-4-amino-1-[[(2R)-1-[[(3R)-1-[[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-6-amino-1-[[(2R)-5-amino-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2R)-6-amino-1-[[(2S)-6-amino-1-[[(2R)-1-[[(2S)-1-[[(2R)-4-amino-1-[[(2S)-1-[[(3S)-1-[[(2S)-1-[[(2R)-1,4-diamino-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]hydrazinyl]-3-hydroxypropanoyl]amino]-4-[[(2R)-1-[[(3S,6S)-6-(chloroamino)-2-methyl-4,5-dioxo-7-phenylheptan-3-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid;2,2,2-trifluoroacetic acid
• InChI: InChI=1S/C148H239ClN44O42.C2HF3O2/c1-19-76(14)116(144(233)183-98(56-73(8)9)133(222)174-94(121(157)210)61-109(154)201)188-141(230)106(67-194)185-137(226)102(63-111(156)203)180-134(223)97(55-72(6)7)177-135(224)99(58-82-38-42-85(198)43-39-82)178-127(216)88(34-24-27-49-151)169-125(214)89(35-25-28-50-152)172-143(232)115(75(12)13)187-123(212)78(16)166-130(219)95(53-70(2)3)175-129(218)92(46-47-108(153)200)171-124(213)87(33-23-26-48-150)168-126(215)90(36-29-51-163-147(158)159)170-132(221)96(54-71(4)5)176-128(217)91(37-30-52-164-148(160)161)173-145(234)117(79(17)196)189-139(228)100(59-83-40-44-86(199)45-41-83)179-136(225)101(62-110(155)202)181-138(227)104(65-113(206)207)184-146(235)118(80(18)197)190-140(229)105(60-84-66-162-69-165-84)192-193-107(68-195)142(231)182-103(64-112(204)205)131(220)167-77(15)122(211)186-114(74(10)11)120(209)119(208)93(191-149)57-81-31-21-20-22-32-81;3-2(4,5)1(6)7/h20-22,31-32,38-45,66,69-80,87-107,114-118,191-199H,19,23-30,33-37,46-65,67-68,150-152H2,1-18H3,(H2,153,200)(H2,154,201)(H2,155,202)(H2,156,203)(H2,157,210)(H,162,165)(H,166,219)(H,167,220)(H,168,215)(H,169,214)(H,170,221)(H,171,213)(H,172,232)(H,173,234)(H,174,222)(H,175,218)(H,176,217)(H,177,224)(H,178,216)(H,179,225)(H,180,223)(H,181,227)(H,182,231)(H,183,233)(H,184,235)(H,185,226)(H,186,211)(H,187,212)(H,188,230)(H,189,228)(H,190,229)(H,204,205)(H,206,207)(H4,158,159,163)(H4,160,161,164);(H,6,7)/t76-,77+,78+,79+,80+,87-,88-,89+,90+,91+,92+,93-,94+,95-,96-,97-,98-,99+,100+,101-,102+,103-,104+,105-,106-,107+,114-,115-,116?,117?,118?;/m0./s1
• InChIKey: WYCNYVQQISKFBK-OBBUXTCFSA-N
• SMILES: CC[C@H](C)C(C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(=O)N)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)C([C@@H](C)O)NC(=O)[C@@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H](CC(=O)O)NC(=O)C([C@@H](C)O)NC(=O)[C@H](CC3=CN=CN3)NN[C@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C)C(=O)N[C@@H](C(C)C)C(=O)C(=O)[C@H](CC4=CC=CC=C4)NCl.C(=O)(C(F)(F)F)O

[D-p-Cl-Phe⁶,Leu¹⁷]-VIP TFA（Cat No.:I045805）is the trifluoroacetate salt form of a modified vasoactive intestinal peptide (VIP) analog. In this peptide, D-para-chlorophenylalanine substitutes at position 6 and leucine at position 17, changes that enhance metabolic stability and alter receptor interactions. VIP and its analogs are important regulators of vasodilation, smooth muscle relaxation, and neuroendocrine signaling. [D-p-Cl-Phe⁶,Leu¹⁷]-VIP TFA is frequently employed to study receptor selectivity, peptide structure–activity relationships, and physiological effects in cardiovascular, neurological, and immunological systems, providing insights into potential therapeutic developments targeting VIP pathways.